CorMedix (CRMD) to Release Earnings on Tuesday

CorMedix (NASDAQ:CRMD - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect CorMedix to post earnings of $0.25 per share and revenue of $38.90 million for the quarter.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.05. During the same period in the prior year, the firm posted ($0.25) EPS. On average, analysts expect CorMedix to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

CorMedix Trading Up 23.6 %

Shares of CRMD stock traded up $2.13 on Tuesday, reaching $11.16. The company had a trading volume of 4,185,248 shares, compared to its average volume of 1,064,145. The stock has a market cap of $756.76 million, a PE ratio of -13.78 and a beta of 1.54. The company has a 50-day moving average of $8.62 and a 200-day moving average of $9.76. CorMedix has a 12 month low of $3.61 and a 12 month high of $13.85.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on CRMD shares. D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of CorMedix in a research report on Tuesday. Leerink Partnrs raised shares of CorMedix to a "strong-buy" rating in a research report on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $12.00 price objective on shares of CorMedix in a research report on Wednesday, March 26th. Leerink Partners started coverage on CorMedix in a report on Friday, March 7th. They set an "outperform" rating and a $18.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $12.00 price target on shares of CorMedix in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $14.50.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.